We contributed to the development of a national strategy for high-cost drugs for rare diseases.

This entry was posted on Wednesday, July 14th, 2021 at 8:35 pm and is filed under . You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.